Evaluation of gradient strip diffusion for susceptibility testing of aztreonam–avibactam in metallo-β-lactamase-producing Enterobacterales
Open Access
- 13 November 2024
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 62 (11) , e0064924
Abstract
The emergence of metallo-β-lactamase (MBL)-producing Enterobacterales presents unique clinical treatment challenges. Recently developed β-lactam/ β-lactamase inhibitor combination agents, while effective against other carbapenemase-producing organisms, are notably ineffective against MBL producers. While MBLs do not hydrolyze monobactams (aztreonam), many MBL-producing organisms are resistant to aztreonam through alternate mechanisms, leaving cefiderocol as the sole monotherapy treatment option recommended for MBL producers. Recent guidelines for the treatment of MBL-harboring organisms have added combination therapy with aztreonam and ceftazidime–avibactam, using ceftazidime–avibactam as a source of the β-lactamase inhibitor avibactam. Current laboratory testing options for the combination of aztreonam–avibactam are limited to broth microdilution (BMD) and broth disk elution (BDE) methods, which are not practical in most clinical laboratories. In this study, we evaluated the performance of aztreonam/avibactam gradient strips on 103 MBL-producing Enterobacterales patient isolates as well as an additional 31 isolates from the CDC AR Bank. All MBL Enterobacterales patient isolates included in this study harbored a New Delhi metallo-β-lactamase ( bla NDM ) gene. Essential agreement of gradient strip minimal inhibitory concentrations (MICs) for patient isolates compared to BMD was 93.2%. While there are no established breakpoints for aztreonam–avibactam, category agreement (CA) for patient isolates was 97.1% when using the CLSI aztreonam breakpoints. There were no major or very major errors observed. There were three minor errors. Precision for aztreonam–avibactam gradient strip diffusion was 100%. These data demonstrate that the use of gradient strip diffusion for aztreonam–avibactam MIC determination in MBL-producing Enterobacterales is a viable option for clinical laboratories.Keywords
This publication has 21 references indexed in Scilit:
- Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018–2022Journal of Global Antimicrobial Resistance, 2024
- Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative InfectionsClinical Infectious Diseases, 2023
- An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-β-Lactam ResistanceOpen Forum Infectious Diseases, 2023
- Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)Clinical Infectious Diseases, 2022
- Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development PipelineAntimicrobial Agents and Chemotherapy, 2020
- Epidemiology of β-Lactamase-Producing PathogensClinical Microbiology Reviews, 2020
- Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae BacteremiaClinical Infectious Diseases, 2016
- Identification of an NDM-5-producing Escherichia coli Sequence Type 167 in a Neonatal Patient in ChinaScientific Reports, 2016
- Widespread Dissemination of Carbapenem-Resistant Escherichia coli Sequence Type 167 Strains Harboring bla NDM-5 in Clinical Settings in ChinaAntimicrobial Agents and Chemotherapy, 2016
- Characterization of a New Metallo-β-Lactamase Gene, bla NDM-1 , and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from IndiaAntimicrobial Agents and Chemotherapy, 2009